IL17A and inflammatory bowel disease: While the mucosal expression of the pro-inflammatory IL17A/B/C/F cytokines was increased in active IBD, it is indeed interesting to note that the pathway scores for the IL-17 signaling pathway, including expression of IL17RC, were consistently lower in active disease and remission as compared to healthy subjects.